Yes, exclusion criteria includes use of L/C, agonists, and MAO-B inhibitors. Amantadine is allowed. Again, this has nothing to do with drug interactions. It is strictly due to study design as it's a lot cleaner to test a drug's efficacy if it is used alone rather than with other drugs. This would be particularly true if using Azilect, where there are also claims of neuroprotection. In actuality, the criteria is to be drug free at time of the start of trial with the anticipation of remaining that way for 3 months. They aren't expecting participants to remain drug free for the full 3 year trial.